Current and Emerging Trends in Breast Cancer: HER2+ and HER2-Low : Episode 3

Article

February 25, 2022

Current and Emerging Trends in Breast Cancer: HER2+ and HER2-Low

This publication provides a summary of key stakeholder insights on the role of antibody-drug conjugates in targeting HER2+ or HER2-low breast cancer and examines clinical trial data on treatment options for HER2+ breast cancer with brain metastases.

EP: 1.Dr. Iyengar on Trastuzumab Deruxtecan in HER2-Low Breast Cancer

EP: 2.Dr. Abdou on the Significance of the DESTINY-Breast03 Trial in HER2-Positive Breast Cancer

EP: 3.Current and Emerging Trends in Breast Cancer: HER2+ and HER2-Low

Related Videos

Sarah Sammons, MD

Yara Abdou, MD

Neil M. Iyengar, MD

Laura Spring, MD

Laura Spring, MD

Corey J. Langer, MD

John F. Lazar, MD

Rodolfo Bordoni, MD

Related Content

Evolving Treatment Strategies: Managing Advanced Prostate Cancer

December 10th 2024

Evolving Treatment Strategies: Managing Advanced Prostate Cancer

Best Practices in Treating Early-Stage NSCLC

July 11th 2024

Best Practices in Treating Early-Stage NSCLC

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

April 11th 2024

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

April 21st 2023

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

April 21st 2023

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

BTK Inhibitors in MCL and CLL

March 10th 2023

BTK Inhibitors in MCL and CLL

Related Content

Evolving Treatment Strategies: Managing Advanced Prostate Cancer

December 10th 2024

Evolving Treatment Strategies: Managing Advanced Prostate Cancer

Best Practices in Treating Early-Stage NSCLC

July 11th 2024

Best Practices in Treating Early-Stage NSCLC

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

April 11th 2024

An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

April 21st 2023

Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

April 21st 2023

Clinical Decision Making in Advanced NSCLC without Actionable Mutations

BTK Inhibitors in MCL and CLL

March 10th 2023

BTK Inhibitors in MCL and CLL

Latest Conference Coverage

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.